Wells Fargo
CMPX icon

Wells Fargo’s Compass Therapeutics CMPX Stock Holding History

Wells Fargo’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
109,793
+62,053
+130% +$183K ﹤0.01% 5077
2026
Q1 		$253K Sell
47,740
-97,058
-67% -$560K ﹤0.01% 4568
2025
Q4 		$778K Buy
144,798
+76,625
+112% +$354K ﹤0.01% 4154
2025
Q3 		$239K Buy
68,173
+15,449
+29% +$48.8K ﹤0.01% 4838
2025
Q2 		$137K Sell
52,724
-8,489
-14% -$17.5K ﹤0.01% 4993
2025
Q1 		$116K Buy
61,213
+1,353
+2% +$3.6K ﹤0.01% 5032
2024
Q4 		$86.8K Buy
59,860
+13,038
+28% +$21.7K ﹤0.01% 5276
2024
Q3 		$86.2K Buy
46,822
+2,012
+4% +$2.51K ﹤0.01% 5103
2024
Q2 		$44.8K Buy
44,810
+12,991
+41% +$19K ﹤0.01% 5342
2024
Q1 		$63K Buy
31,819
+4,091
+15% +$7.07K ﹤0.01% 5162
2023
Q4 		$43.3K Buy
27,728
+5,536
+25% +$9.58K ﹤0.01% 5329
2023
Q3 		$43.7K Sell
22,192
-12,928
-37% -$32K ﹤0.01% 5247
2023
Q2 		$112K Buy
35,120
+33,783
+2,527% +$106K ﹤0.01% 4973
2023
Q1 		$4.37K Buy
1,337
+701
+110% +$2.75K ﹤0.01% 6085
2022
Q4 		$3.2K Buy
636
+179
+39% +$714 ﹤0.01% 5892
2022
Q3 		$1K Buy
+457
New +$1.26K ﹤0.01% 6304

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wells Fargo's CMPX Position: Q2 2026 in Review

Wells Fargo increased its Compass Therapeutics (CMPX) stake by 130% in Q2 2026, buying an estimated $183K and bringing the position to 109,793 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #5077.

Wells Fargo first reported a position in CMPX in Q3 2022 and has held it in 16 quarters since. The position peaked at $778K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Wells Fargo held 109,793 shares of Compass Therapeutics worth $240K as of Q2 2026.
  • Wells Fargo bought 62,053 Compass Therapeutics shares in Q2 2026, an estimated $183K.
  • Compass Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5077 holding.
  • Wells Fargo first reported a position in Compass Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Wells Fargo's Compass Therapeutics position peaked at $778K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.